Avastin Fails First-Line Pancreatic Cancer Trial, But Pancreatic Program Will Continue
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech and partner Roche await results from another first-line pancreatic cancer trial, AVITA, with enrollment slated to complete by year-end.
You may also be interested in...
Avastin Added To Tarceva/Gemcitabine Fails To Prolong Survival In Phase III Pancreatic Cancer Trial
Roche-sponsored trial did not meet the primary endpoint of overall survival, but did show some clinical benefits.
Avastin Added To Tarceva/Gemcitabine Fails To Prolong Survival In Phase III Pancreatic Cancer Trial
Roche-sponsored trial did not meet the primary endpoint of overall survival, but did show some clinical benefits.
Sanofi Positioning Aflibercept To Compete With Genentech’s Avastin In Certain Settings
Company plans to file VEGF Trap for its first indication, ovarian cancer, in 2008, followed by second-line lung cancer and second-line colorectal cancer.